Role of ultraviolet-b irradiance and vitamin d in reducing risk of cancer

Recent Avenue to Cancer Prevention

Volumn , Issue , 2014, Pages 149-180

  Grant, William B ^a   Moukayed, Meis ^b  

^a Sunlight   (United States)

^b AMERICAN UNIVERSITY IN DUBAI   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84954313420     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (164)

1. Garland, C. F., Garland, F. C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 9:227-231, 1980.
2. Garland, C., Shekelle, R. B., Barrett-Connor, E., Criqui, M. H., Rossof, A. H., Paul, O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. 1:307-309, 1985.
3. Garland, C. F., Comstock, G. W., Garland, F. C., Helsing, K. J., Shaw, E. K., Gorham, E. D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 2:1176-1178, 1989.
4. Garland, F. C., Garland, C. F., Gorham, E. D., Young, J. F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 19:614-622, 1990.
5. Lefkowitz, E. S., Garland, C. F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int. J. Epidemiol. 23:1133-1136, 1994.
6. Astbury, A. Non uniformity in cancer mortality in the US and Australia appears to share a common pathway. Triumf report, TRI-PP-05-01, 2005. http://www.triumf.ca/ publications/pub/arch05/pp-05-01.pdf (accessed Nov. 21, 2011).
7. Van Leeuwen, M. T., Jennifer J. Turner, Michael O. Falster, Nicola S. Meagher, David J. Joske, Andrew E. Grulich, Graham G. Giles and Claire M. Vajdic. Latitude gradients for lymphoid neoplasm subtypes in australia support an association with ultraviolet radiation exposure. Int. J. Cancer. 133:944-951, 2013.
8. Neale, R. E., Youlden, D. R., Krnjacki, L., Kimlin, M. G., van der Pols, J. C. Latitude variation in pancreatic cancer mortality in Australia. Pancreas. 38:387-390, 2009.
9. Grant, W. B. Does solar ultraviolet irradiation affect cancer mortality rates in China? Asian Pac. J. Cancer Prev. 8:236-242, 2007.
10. Chen, W., Clements, M., Rahman, B., Zhang, S., Qiao, Y., Armstrong, B. K. Relationship between cancer mortality/incidence and ambient ultraviolet B irradiance in China. Cancer Causes Control. 21:1701-1709, 2010.
11. Chen, W., Armstrong, B. K., Rahman, B., Zheng, R., Zhang, S., Clements, M. Relationship between cancer survival and ambient ultraviolet B irradiance in China. Cancer Causes Control. 24:1323-1330, 2013.
12. Grant, W. B. An ecological study of cancer incidence and mortality rates in France with respect to latitude, an index for vitamin D production. Dermatoendocrinol. 2:62-67, 2010.
13. Mizoue, T. Ecological study of solar radiation and cancer mortality in Japan. Health Phys. 87:532-538, 20004.
14. Kinoshita, S., Wagatsuma, Y., Okada, M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. Int. J. Health Geogr. 6:34, 2007.
15. Grant, W. B. Role of solar UV irradiance and smoking in cancer as inferred from cancer incidence rates by occupation in Nordic countries. Dermatoendocrinol. 4:203- 211, 2012.
16. Grant, W. B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UV irradiance and smoking. Int. J. Cancer. 120:1123-1127, 2007.
17. Grant, W. B. An estimate of premature cancer mortality in the US due to inadequate doses of solar ultraviolet-B radiation. Cancer. 94:1867-1875, 2002.
18. Grant, W. B. Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J. Natl. Med. Assoc. 98:357-364, 2006.
19. Grant, W. B., Garland, C. F. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 26:2687-2699, 2006.
20. Boscoe, F. P., Schymura, M. J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2000. BMC Cancer. 6:264, 2006.
21. Mohr, S. B. A brief history of vitamin D and cancer prevention. Ann. Epidemiol. 19:79- 83, 2009.
22. Grant, W. B., Mohr, S. B. Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Ann. Epidemiol. 19:446-454, 2009.
23. Grant, W. B. Ecological studies of the UVB-vitamin D-cancer hypothesis; review. Anticancer Res. 32:223-236, 2012.
24. Grant, W. B. A review of the evidence regarding the solar ultraviolet-B-vitamin D- cancer hypothesis. Standardy Medyczne/Pediatria. 9:610-619, 2012.
25. Grant, W. B. Update on evidence that support a role of solar ultraviolet-B irradiance in reducing cancer risk. Anticancer Agents Med. Chem. 13:140-146, 2013.
26. Grant, W. B. A review of evidence that ultraviolet-B irradiance and vitamin D reduce risk for cancer. US Endocrinology. 9:50-54, 2013.
27. Lin, S. W., Wheeler, D. C., Park, Y., Cahoon, E. K., Hollenbeck, A. R., Freedman, D. M., Abnet, C. C. Prospective study of ultraviolet radiation exposure and risk of cancer in the US. Int. J. Cancer. 131:E1015-E1023, 2012.
28. Fioletov, V. E., McArthur, L. J., Mathews, T. W., Marrett, L. Estimated ultraviolet exposure levels for a sufficient vitamin D status in North America. J. Photochem. Photobiol. B. 100:57-66, 2010.
29. Grant, W. B. An ecological study of cancer mortality rates in the United States with respect to solar ultraviolet-B doses, smoking, alcohol consumption, and urban/rural residence. Dermatoendocrinol. 2:68-76, 2010.
30. Grant, W. B. Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level; implications for meta-analyses and setting vitamin D guidelines. Dermatoendocrinol. 3:199-204, 2011.
31. Abbas, S., Linseisen, J., Slanger, T., Kropp, S., Mutschelknauss, E., Flesch-Janys, D., Chang-Claude, J. Serum 25-hydroxyvitamin D and risk of postmenopausal breast cancer-results of a large case-control study. Carcinogenesis. 29:93-99, 2008.
32. Abbas, S., Chang-Claude, J., Linseisen, J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int. J. Cancer. 124: 250-255, 2009.
33. Fedirko, V., Riboli, E., Tjønneland, A., Ferrari, P., Olsen, A., Bueno-de-Mesquita, H. B., van Duijnhoven, F. J., Norat, T., Jansen, E. H., Dahm, C. C., Overvad, K., Boutron- Ruault, M. C., Clavel-Chapelon, F., Racine, A., Lukanova, A., Teucher, B., Boeing, H., Aleksandrova, K., Trichopoulou, A., Benetou, V., Trichopoulos, D., Grioni, S., Vineis, P., Panico, S., Palli, D., Tumino, R., Siersema, P. D., Peeters, P. H., Skeie, G., Brustad, M., Chirlaque, M. D., Barricarte, A., Ramón Quirós, J., Sánchez, M. J., Dorronsoro, M., Bonet, C., Palmqvist, R., Hallmans, G., Key, T. J., Crowe, F., Khaw, K. T., Wareham, N., Romieu, I., McKay, J., Wark, P. A., Romaguera, D., Jenab, M. Prediagnostic 25- hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol. Biomarkers Prev. 21:582-593, 2012.
34. Lowe, L. C., Guy, M., Mansi, J. L., Peckitt, C., Bliss, J., Wilson, R. G., Colston, K. W. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer. 41:1164-1169, 2005.
35. Crew, K. D., Gammon, M. D., Steck, S. E., Hershman, D. L., Cremers, S., Dworakowski, E., Shane, E., Terry, M. B., Desai, M., Teitelbaum, S. L., Neugut, A. I., Santella, R. M. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev. Res. (Phila. Pa). 2:598-604, 2009.
36. Bakhru, A., Mallinger, J. B., Buckanovich, R. J., Griggs, J. J. Casting light on 25- hydroxyvitamin D deficiency in ovarian cancer: A study from the NHANES. Gynecol. Oncol. 119:314-318, 2010.
37. Lurie, G., Matsuno, R. K., Wilkens, L. R., Thompson, P. J., Ollberding, N. J., Carney, M. E., Goodman, M. T. Cataract and ovarian carcinoma: Is the vitamin D hypothesis alive? Cancer Epidemiol. Biomarkers Prev. 202507-2011, 2011.
38. Helzlsouer, K. J., Gallicchio, L. Shedding light on serum vitamin D concentrations and the risk of rarer cancers. Anticancer Agents Med. Chem. 13:65-69, 2013.
39. Grant, W. B. Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J. Photochem. Photobiol. B. 101:130- 136, 2010.
40. Grant, W. B. Effect of follow-up time on the relation between prediagnostic serum 25- hydroxyitamin D and all-cause mortality rate. Dermatoendocrinol. 4:198-202, 2012.
41. Oh, E. Y., Ansell, C., Nawaz, H., Yang, C. H., Wood, P. A., Hrushesky, W. J. Global breast cancer seasonality. Breast Cancer Res. Treat. 123:233-243, 2010.
42. Hyppönen, E., Power, C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am. J. Clin. Nutr. 85:860-868, 2007.
43. Helzlsouer, K. J. For the VDPP Steering Committee. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epi. 172: 4-9, 2010.
44. Lim, U., Freedman, D. M., Hollis, B. W., Horst, R. L., Purdue, M. P., Chatterjee, N., Weinstein, S. J., Morton, L. M., Schatzkin, A., Virtamo, J., Linet, M. S., Hartge, P., Albanes, D. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int. J. Cancer. 124:979-986, 2009.
45. Stolzenberg-Solomon, R. Z., Vieth, R., Azad, A., Pietinen, P., Taylor, P. R., Virtamo, J., Albanes, D. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 66:10213-10219, 2006.
46. Stolzenberg-Solomon, R. Z., Hayes, R. B., Horst, R. L., Anderson, K. E., Hollis, B. W., Silverman, D. T. Serum vitamin D and risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Screening Trial. Cancer Res. 69:1439-1447, 2009.
47. Wolpin, B. M., Ng, K., Bao, Y., Kraft, P., Stampfer, M. J., Michaud, D. S., Ma, J., Buring, J. E., Sesso, H., Lee, I. M., Rifai, N., Cochrane, B. B., Wactawaski-Wende, J., Chlebowski, R. T., Willett, W. C., Manson, J. E., Giovannucci, E. L., Fuchs, C. S. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 21:82-91, 2012.
48. Vieth, R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res. 29:3675-684, 2009.
49. Tuohimaa, P., Tenkanen, L., Ahonen, M., Lumme, S., Jellum, E., Hallmans, G., Stattin, P., Harvei, S., Hakulinen, T., Luostarinen, T., Dillner, J., Lehtinen, M., Hakama, M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer. 108:104-108, 2004.
50. Giovannucci, E., Liu, Y., Rimm, E. B., Hollis, B. W., Fuchs, C. S., Stampfer, M. J., Willett, W. H. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. JNCI 98:451-459, 2006.
51. Brinkman, M. T., Karagas, M. R., Zens, M. S., Schned, A., Reulen, R. C., Zeegers, M. P. Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire Study. Cancer Causes Control. 21:609-619, 2010.
52. Mondul, A. M., Weinstein, S. J., Männistö, S., Snyder, K., Horst, R. L., Virtamo, J., Albanes, D. Serum vitamin D and risk of bladder cancer. Cancer Res. 70:9218-9223, 2010.
53. Mondul, A. M., Weinstein, S. J., Horst, R. L., Purdue, M. P., Albanes, D. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. Biomarkers Prev. 21:1222-1225, 2012.
54. Afzal, S., Bojesen, S. E., Nordestgaard, B. G. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin. Chem. 59:771-780, 2013.
55. Yin, L., Grandi, N., Raum, E., Haug, U., Arndt, V., Brenner, H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecol. Oncol. 121:369-375, 2011.
56. Toriola, A. T., Surcel, H. M., Calypse, A., Grankvist, K., Luostarinen, T., Lukanova, A., Pukkala, E., Lehtinen, M. Independent and joint effects of serum 25- hydroxyvitamin D and calcium on ovarian cancer risk: A prospective nested casecontrol study. Eur. J. Cancer. 46:2799-2805, 2010.
57. Yin, L., Raum, E., Haug, U., Arndt, V., Brenner, H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 33:435-445, 2009.
58. Gandini, S., Boniol, M., Haukka, J., Byrnes, G., Cox, B., Sneyd, M. J., Mullie, P., Autier, P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer. 128: 1414-1424, 2011.
59. Gilbert, R., Martin, R. M., Beynon, R., Harris, R., Savovic, J., Zuccolo, L., Bekkering, G. E., Fraser, W. D., Sterne, J. A., Metcalfe, C. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response metaanalysis. Cancer Causes Control. 22:319-340, 2011.
60. Gilbert, R., Metcalfe, C., Fraser, W. D., Donovan, J., Hamdy, F., Neal, D. E., Athene Lane, J., Martin, R. M. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int. J. Cancer. 131:1187-1196, 2012.
61. Pilz, S., Kienreich, K., Tomaschitz, A., Ritz, E., Lerchbaum, E., Obermayer-Pietsch, B., Matzi, V., Lindenmann, J., März, W., Gandini, S., Dekker, J. M. Vitamin D and cancer mortality: Systematic review of prospective epidemiological studies. Anticancer Agents Med. Chem. 13:107-117, 2013.
62. Vrieling, A., Hein, R., Abbas, S., Schneeweiss, A., Flesch-Janys, D., Chang-Claude, J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res. 13:R74, 2011.
63. Tretli, S., Schwartz, G. G., Torjesen, P. A., Robsahm, T. E. Serum levels of 25- hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 23:363-370, 2012.
64. Goodwin, P. J., Ennis, M., Pritchard, K. I., Koo, J., Hood, N. Prognostic effects of 25- hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 27:3757-3763, 2009.
65. Ng, K., Wolpin, B. M., Meyerhardt, J. A., Wu, K., Chan, A. T., Hollis, B. W., Giovannucci, E. L., Stampfer, M. J., Willett, W. C., Fuchs, C. S. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br. J. Cancer. 101:916-923, 2009.
66. Mezawa, H., Sugiura, T., Watanabe, M., Norizoe, C., Takahashi, D., Shimojima, A., Tamez, S., Tsutsumi, Y., Yanaga, K., Urashima, M. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer. 10:347, 2010.
67. Ng, K., Sargent, D. J., Goldberg, R. M., Meyerhardt, J. A., Green, E. M., Pitot, H. C., Hollis, B. W., Pollak, M. N., Fuchs, C. S. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J. Clin. Oncol. 29:1599-606, 2011.
68. Ren, C., Qiu, M. Z., Wang, D. S., Luo, H. Y., Zhang, D. S., Wang, Z. Q., Wang, F. H., Li, Y. H., Zhou, Z. W., Xu, R. H. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. J. Transl. Med. 10:16, 2012.
69. Meyer, F., Liu, G., Douville, P., Samson, E., Xu, W., Adjei, A., Bairati, I. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. Int. J. Cancer. 128:1741-1746, 2011.
70. Pardanani, A., Drake, M. T., Finke, C., Lasho, T. L., Rozell, S. A., Jimma, T., Tefferi, A. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Am. J. Hematol. 86:1013-1016, 2011.
71. Zhou, W., Heist, R. S., Liu, G., Asomaning, K., Neuberg, D. S., Hollis, B. W., Wain, J. C., Lynch, T. J., Giovannucci, E., Su, L., Christiani, D. C. Circulating 25- hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol. 25:479-485, 2007.
72. Drake, M. T., Maurer, M. J., Link, B. K., Habermann, T. M., Ansell, S. M., Micallef, I. N., Kelly, J. L., Macon, W. R., Nowakowski, G. S., Inwards, D. J., Johnston, P. B., Singh, R. J., Allmer, C., Slager, S. L., Weiner, G. J., Witzig, T. E., Cerhan, J. R. Vitamin D isufficiency and pognosis in non-Hodgkin's lmphoma. J. Clin. Oncol. 28: 4191-4198, 2010.
73. Shanafelt, T. D., Drake, M. T., Maurer, M. J., Allmer, C., Rabe, K. G., Slager, S. L., Weiner, G. J., Call, T. G., Link, B. K., Zent, C. S., Kay, N. E., Hanson, C. A., Witzig, T. E., Cerhan, J. R. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia (CLL). Blood. 117:1492-1498, 2011.
74. Newton-Bishop, J. A., Beswick, S., Randerson-Moor, J., Chang, Y. M., Affleck, P., Elliott, F., Chan, M., Leake, S., Karpavicius, B., Haynes, S., Kukalizch, K., Whitaker, L., Jackson, S., Gerry, E., Nolan, C., Bertram, C., Marsden, J., Elder, D. E., Barrett, J. H., Bishop, D. T. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J. Clin. Oncol. 27:5439-5444, 2009.
75. Fang, F., Kasperzyk, J. L., Shui, I., Hendrickson, W., Hollis, B. W., Fall, K., Ma, J., Gaziano, J. M., Stampfer, M. J., Mucci, L. A., Giovannucci, E. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 6: e18625, 2011.
76. Gugatschka, M., Kiesler, K., Obermayer-Pietsch, B., Groselj-Strele, A., Griesbacher, A., Friedrich, G. Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur. Arch. Otorhinolaryngol. 268:1201-1204, 2011.
77. Ginde, A. A., Liu, M. C., Camargo, C. A. Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch. Intern. Med. 169:626- 632, 2009.
78. Grant, W. B., Peiris, A. N. Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and White Americans. Dermatoendocrinol. 4:85-94, 2012.
79. Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O'Sullivan, M. J., Margolis, K. L., Ockene, J. K., Phillips, L., Pottern, L., Prentice, R. L., Robbins, J., Rohan, T. E., Sarto, G. E., Sharma, S., Stefanick, M. L., Van Horn, L., Wallace, R. B., Whitlock, E., Bassford, T., Beresford, S. A., Black, H. R., Bonds, D. E., Brzyski, R. G., Caan, B., Chlebowski, R. T., Cochrane, B., Garland, C., Gass, M., Hays, J., Heiss, G., Hendrix, S. L., Howard, B. V., Hsia, J., Hubbell, F. A., Jackson, R. D., Johnson, K. C., Judd, H., Kooperberg, C. L., Kuller, L. H., LaCroix, A. Z., Lane, D. S., Langer, R. D., Lasser, N. L., Lewis, C. E., Limacher, M. C., Manson, J. E.; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354:684-696, 2006.
80. Lappe, J. M., Travers-Gustafson, D., Davies, K. M., Recker, R. R., Heaney, R. P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 85:1586-1591, 2007.
81. Avenell, A., Maclennan, G. S., Jenkinson, D. J., McPherson, G. C., McDonald, A. M., Pant, P. R., Grant, A. M., Campbell, M. K., Anderson, F. H., Cooper, C., Francis, R. M., Gillespie, W. J., Robinson, C. M., Torgerson, D. J., Wallace, W. A.; the RECORD Trial Group. Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). J. Clin. Endocrinol. Metab. 97:614-622, 2012.
82. Bolland, M. J., Grey, A., Gamble, G. D., Reid, I. R. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am. J. Clin. Nutr. 94:1144-1149, 2011.
83. Lappe, J. M., Heaney, R. P. Why randomized controlled trials of calcium and vitamin D sometimes fail. Dermatoendocrin. 4:95-100, 2012.
84. Kristal, A. R. Are clinical trials the "gold standard" for cancer prevention research? Cancer Epidemiol. Biomarkers Prev. 17:3289-3291, 2008.
85. Pukkala, E., Martinsen, J. I., Lynge, E., Gunnarsdottir, H. K., Sparén, P., Tryggvadottir, L., Weiderpass, E., Kjaerheim, K. Occupation and cancer-follow-up of 15 million people in five Nordic countries. Acta Oncol. 48:646-790, 2009.
86. Tynes, T., Hannevik, M., Andersen, A., Vistnes, A. I., Haldorsen, T. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control. 7: 197-204, 1996.
87. Coleman, M. P., Reiter, R. J. Breast cancer, blindness and melatonin. Eur. J. Cancer. 1992; 28(2-3):501-3.
88. Schernhammer, E. S., Razavi, P., Li, T. Y., Qureshi, A. A., Han, J. Rotating night shifts and risk of skin cancer in the nurses' health study. J. Natl. Cancer Inst. 103:602-606, 2011.
89. Parent, M. é., El-Zein, M., Rousseau, M. C., Pintos, J., Siemiatycki, J. Night work and the risk of cancer among men. Am. J. Epidemiol. 176:751-759, 2012.
90. Grant, W. B. Re: "Night work and the risk of cancer among men"; author reply. Am. J. Epidemiol. 177:1165-1166, 2013.
91. Shay, J. W., Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33:787-91, 1997.
92. Blackburn, E. H. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 579:859-862, 2005.
93. Kasiappan, R., Shen, Z., Tse, A. K., Jinwal, U., Tang, J., Lungchukiet, P., Sun, Y., Kruk, P., Nicosia, S. V., Zhang, X., Bai, W. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J. Biol. Chem. 287:41297-41309, 2012.
94. Jiang, F., Bao, J., Li, P., Nicosia, S. V., Bai, W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J. Biol. Chem. 279(51):53213-53221, 2004.
95. Ikeda, N., Uemura, H., Ishiguro, H., Hori, M., Hosaka, M., Kyo, S., Miyamoto, K., Takeda, E., Kubota, Y. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol. Cancer Ther. 2:739-746, 2003.
96. Hisatake, J., Kubota, T., Hisatake, Y., Uskokovic, M., Tomoyasu, S., Koeffler, H. P. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res. 59(16):4023-4029, 1999.
97. Bao, A., Li, Y., Tong, Y., Zheng, H., Wu, W., Wei, C. Tumor-suppressive effects of 1,25-dihydroxyvitamin D3 in gastric cancer cells. Hepatogastroenterology 60(126), 2013.
98. Akutsu, N., Lin, R., Bastien, Y., Bestawros, A., Enepekides, D. J., Black, M. J., White, J. H. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. Mol. Endocrinol. 15:1127-1139, 2001.
99. Chiang, K. C., Yeh, C. N., Chen, S. C., Shen, S. C., Hsu, J. T., Yeh, T. S., Pang, J. H., Su, L. J., Takano, M., Kittaka, A., Juang, H. H., Chen, T. C. MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1a,25-Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells. Evid. Based Complement Alternat. Med. 2012;2012:310872.
100. Baudet, C., Chevalier, G., Chassevent, A., Canova, C., Filmon, R., Larra, F., Brachet, P., Wion, D. 1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. J. Neurosci. Res. 46:540-550, 1996.
101. Bao, B. Y., Hu, Y. C., Ting, H. J., Lee, Y. F. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene. 23: 3350-3360, 2004.
102. Chatterjee, M. Vitamin D and genomic stability. Mutat. Res. 475:69-87, 2001.
103. De Haes, P., Garmyn, M., Verstuyf, A., De Clercq, P., Vandewalle, M., Degreef, H., Vantieghem, K., Bouillon, R., Segaert, S. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J. Photochem. Photobiol. B. 78:141-148, 2005.
104. Banakar, M. C., Paramasivan, S. K., Chattopadhyay, M. B., Datta, S., Chakraborty, P., Chatterjee, M., Kannan, K., Thygarajan, E. 1alpha, 25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J. Gastroenterol. 10:1268- 1275, 2004.
105. Ting, H. J., Yasmin-Karim, S., Yan, S. J., Hsu, J. W., Lin, T. H., Zeng, W., Messing, J., Sheu, T. J., Bao, B. Y., Li, W. X., Messing, E., Lee, Y. F. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res. 72(4):958-968, 2012.
106. Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 160:1-40, 2006.
107. Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39:44-84, 2007.
108. Losso, J. N., Bawadi, H. A. Hypoxia inducible factor pathways as targets for functional foods. J. Agric. Food Chem. 53:3751-3768, 2005.
109. Peehl, D. M., Shinghal, R., Nonn, L., Seto, E., Krishnan, A. V., Brooks, J. D., Feldman, D. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92:131-141, 2004.
110. Bao, B. Y., Ting, H. J., Hsu, J. W., Lee, Y. F. Protective role of 1 alpha, 25- dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int. J. Cancer. 122:2699-2706, 2008.
111. Fleet, J. C., Desmet, M., Johnson, R., Li, Y. Vitamin D and cancer:a review of molecular mechanisms. Biochem. J. 441:61-76, 2012.
112. Ben-Shoshan, M., Amir, S., Dang, D. T., Dang, L. H., Weisman, Y., Mabjeesh, N. J. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor- 1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer Ther. 6: 1433-1439, 2007.
113. Chung, I., Han, G., Seshadri, M., Gillard, B. M., Yu, W. D., Foster, B. A., Trump, D. L., Johnson, C. S. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 69(3): 967-975, 2009.
114. Lundqvist, J., Hansen, S. K., Lykkesfeldt, A. E. Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase. Biochim. Biophys. Acta. 1833:40- 47, 2013.
115. Dormoy, V., Béraud, C., Lindner, V., Coquard, C., Barthelmebs, M., Brasse, D., Jacqmin, D., Lang, H., Massfelder, T. Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma. Carcinogenesis. 2012 Nov.;33(11):2084-2093, 2012.
116. Yu, H., Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 92:1472-1489, 2000.
117. Figueroa, J. A., De Raad, S., Tadlock, L., Speights, V. O., Rinehart, J. J. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J. Urol. 159:1379-1383, 1998.
118. Krishnan, A. V., Shinghal, R., Raghavachari, N., Brooks, J. D., Peehl, D. M., Feldman, D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 59:243-251, 2004.
119. Kriebitzsch, C., Verlinden, L., Eelen, G., Tan, B. K., Van Camp, M., Bouillon, R., Verstuyf, A. The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells--a microarray approach. Anticancer Res. 29:3471-3483, 2009.
120. Lee, H. J., Liu, H., Goodman, C., Ji, Y., Maehr, H., Uskokovic, M., Notterman, D., Reiss, M., Suh, N. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem. Pharmacol. 72: 332-343, 2006.
121. Swami, S., Raghavachari, N., Muller, U. R., Bao, Y. P., Feldman, D. Vitamin D growth inhibition of breast cancer cells:gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 80:49-62, 121.
122. Proietti, S., Cucina, A., D'Anselmi, F., Dinicola, S., Pasqualato, A., Lisi, E., Bizzarri, M. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells. J. Pineal. Res. 50:150- 158, 2011.
123. Yang, L., Yang, J., Venkateswarlu, S., Ko, T., Brattain, M. G. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J. Cell Physiol. 188:383-393, 2001.
124. Chen, A., Davis, B. H., Sitrin, M. D., Brasitus, T. A., Bissonnette, M. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am. J. Physiol. Gastrointest. Liver Physiol. 283:G864-G874, 2002.
125. Tong, W. M., Hofer, H., Ellinger, A., Peterlik, M., Cross, H. S. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol. Res. 11:77-84, 1999.
126. Yanagisawa, J., Yanagi, Y., Masuhiro, Y., Suzawa, M., Watanabe, M., Kashiwagi, K., Toriyabe, T., Kawabata, M., Miyazono, K., Kato, S. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 283:1317-1321, 1999.
127. Deeb, K. K., Trump, D. L., Johnson, C. S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer. 7:684-700, 2007.
128. Louderbough, J. M., Schroeder, J. A.Understanding the dual nature of CD44 in breast cancer progression. Mol. Cancer Res. 9:1573-1586, 2011.
129. So, J. Y., Lee, H. J., Smolarek, A. K., Paul, S., Wang, C. X., Maehr, H., Uskokovic, M., Zheng, X., Conney, A. H., Cai, L., Liu, F., Suh, N. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol. Pharmacol. 79: 360-367, 2011.
130. Marotta, L. L., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., Wu, Z., Gönen, M., Mulvey, L. A., Bessarabova, M. O., Huh, S. J., Silver, S. J., Kim, S. Y., Park, S. Y., Lee, H. E., Anderson, K. S., Richardson, A. L., Nikolskaya, T., Nikolsky, Y., Liu, X. S., Root, D. E., Hahn, W. C., Frank, D. A., Polyak, K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121(7):2723-2735, 2011.
131. So, J. Y., Smolarek, A. K., Salerno, D. M., Maehr, H., Uskokovic, M., Liu, F., Suh, N. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One. 8:e54020, 2013.
132. Xie, T. X., Wei, D., Liu, M., Gao, A. C., Ali-Osman, F., Sawaya, R., Huang, S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 23:3550-60, 2004.
133. Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., Bromberg, J. F. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. US 101:10602- 10607, 2004.
134. Hsieh, F. C., Cheng, G., Lin, J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 335(2):292-299, 2005.
135. Meephansan, J., Komine, M., Tsuda, H., Ohtsuki, M. Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line. Clin. Exp. Dermatol. 37:889-896, 2012.
136. Duffy, M. J., Maguire, T. M., Hill, A., McDermott, E., O'Higgins, N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:252-257, 2000.
137. Schlange, T., Matsuda, Y., Lienhard, S., Huber, A., Hynes, N. E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 9:R63, 2007.
138. Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., Zack, T. I., Wang, X., Tsherniak, A., Schinzel, A. C., Shao, D. D., Schumacher, S. E., Weir, B. A., Vazquez, F., Cowley, G. S., Root, D. E., Mesirov, J. P., Beroukhim, R., Kuo, C. J., Goessling, W., Hahn, W. C. ß-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 151:1457-1473, 2012.
139. Behrens, J. Everything you would like to know about wnt signaling. Science signaling. 6:pe17, 2013.
140. Vadlakonda, L., Pasupuleti, M., Pallu, R. Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells. Front. Oncol. 3: 85, 2013.
141. Brabletz, T., Jung, A., Dag, S., Hlubek, F., Kirchner, T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155: 1033-1038, 1999.
142. Nusse, R., Varmus, H. E. Wnt genes. Cell. 1992 Jun. 26;69(7):1073-87.
143. Nusse, R. The Wnt gene family in tumorigenesis and in normal development. J. Steroid Biochem. Mol. Biol. 43:9-12, 1992.
144. Jamora, C., DasGupta, R., Kocieniewski, P., Fuchs, E. Links between signal transduction, transcription and adhesion in epithelial bud development. Nature. 422: 317-322, 2003.
145. Moukayed, M., Grant, W. B. Molecular link between vitamin D and cancer prevention. Nutrients, 2013;5:3993-4023.
146. Jamora, C., DasGupta, R., Kocieniewski, P., Fuchs, E. Links between signal transduction, transcription and adhesion in epithelial bud development. Nature. 422: 317-322, 2003.
147. Kovalenko, P. L., Zhang, Z., Cui, M., Clinton, S. K., Fleet, J. C. 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics. 11:26, 2010.
148. Pálmer, H. G., González-Sancho, J. M., Espada, J., Berciano, M. T., Puig, I., Baulida, J., Quintanilla, M., Cano, A., de Herreros, A. G., Lafarga, M., Muñoz, A. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell. Biol. 154:369-387, 2001.
149. Pendás-Franco, N., Aguilera, O., Pereira, F., González-Sancho, J. M., Muñoz, A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res. 28:2613-2623, 2008.
150. Beildeck, M. E., Islam, M., Shah, S., Welsh, J., Byers, S. W. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One. 4:e7872, 2009.
151. Rohan, J. N., Weigel, N. L. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 150:2046-2054, 2009.
152. Rawson, J. B., Sun, Z., Dicks, E., Daftary, D., Parfrey, P. S., Green, R. C., Gallinger, S., McLaughlin, J. R., Wang, P. P., Knight, J. A., Bapat, B. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients. Nutr. Cancer. 64:919-928, 2012.
153. Aguilera, O., Peña, C., García, J. M., Larriba, M. J., Ordóñez-Morán, P., Navarro, D., Barbáchano, A., López de Silanes, I., Ballestar, E., Fraga, M. F., Esteller, M., Gamallo, C., Bonilla, F., González-Sancho, J. M., Muñoz, A. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis. 28:1877-1884, 2007.
154. Kaler, P., Augenlicht, L., Klampfer, L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 28:3892-3902, 2009.
155. Bao, B. Y., Yao, J., Lee, Y. F. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin- 8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 27:1883-1893, 2006.
156. Tse, A. K., Zhu, G. Y., Wan, C. K., Shen, X. L., Yu, Z. L., Fong, W. F. 1alpha,25- Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol. Immunol. 47:1728-1738, 2010.
157. Høyer-Hansen, M., Jäättelä, M. Autophagy: an emerging target for cancer therapy. Autophagy. 4:574-580, 2008.
158. Bristol, M. L., Di, X., Beckman, M. J., Wilson, E. N., Henderson, S. C., Maiti, A., Fan, Z., Gewirtz, D. A. Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D3. Autophagy. 8:739-753, 2012.
159. Mathew, R., Kongara, S., Beaudoin, B., Karp, C. M., Bray, K., Degenhardt, K., Chen, G., Jin, S., White, E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 21:1367-1381, 2007.
160. Karantza-Wadsworth, V., Patel, S., Kravchuk, O., Chen, G., Mathew, R., Jin, S., White, E. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 21:1621-1635, 2007.
161. Hill, A. B. The environment and disease: Association or causation? Proc. R. Soc. Med. 58: 295-300, 1965.
162. Potischman, N., Weed, D. L. Causal criteria in nutritional epidemiology. Am. J. Clin. Nutr. 69:1309S-1314S, 1999.
163. Grant, W. B. How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer? An examination using Hill's criteria for causality. Dermatoendocrinol. 1:17-24, 2009.
164. Mohr, S. B., Gorham, E. D., Alcaraz, J. E., Kane, C. I., Macera, C. A., Parsons, J. E., Wingard, D. L., Garland, C. F. Does the evidence for an inverse relationship between serum vitamin D status and breast cancer risk satisfy the Hill criteria? Dermatoendocrin. 4:152-157, 2012.